Tokyo: The Biomedical Division of PHC Corporation, a subsidiary of PHC Holdings Corporation, has announced an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform in Japan. The agreement marks a significant development in the availability of advanced cell engineering technologies in the Japanese market.

According to BERNAMA News Agency, SciMed (Asia) Pte Ltd, another subsidiary of PHC Holdings, had previously entered into a similar exclusive distribution agreement with MaxCyte in Singapore, launching the ExPERT platform in the country in June. MaxCyte is recognized for its contributions to cell-engineering through platform technologies that support the discovery, development, and commercialization of next-generation cell therapeutics.

Under the new partnership, PHCbi will provide sales and service support for MaxCyte's instruments, consumables, and solutions. This will enable Japanese researchers and manufacturers to access a clinically proven, non-viral cell engineering platform. The ExPERT instrument portfolio is renowned for its advanced electroporation technology, which is critical for efficient and scalable cell engineering. The platform's ability to deliver high transfection efficiency and cell viability makes it a valuable tool in the development of biological and cellular therapeutics.